Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
digoxin + fimasartan
- Development stage
- Phase 1
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination involves **digoxin**, a cardiac glycoside used to treat heart failure and atrial fibrillation by increasing myocardial contraction and controlling heart rate, and **fimasartan**, an angiotensin II receptor antagonist used to treat hypertension and heart failure by inhibiting vasoconstriction and reducing aldosterone secretion. The combination may be used to manage conditions where both drugs are beneficial, though specific clinical use may vary based on patient needs and interactions.
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)ATP1A (Sodium/potassium-transporting ATPase)
Beyond the preview
Go deeper on digoxin + fimasartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on digoxin + fimasartan.